Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 55 EV-to-EBITDA is -1.55 as of Aug. 30, 2026. GuruFocus rates TSE:4882 with a GF Score™ of 55/100 and a GF Value™ of 円442.02 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 730 Drug Manufacturers companies, Perseus Proteomics ranks worse than 136986.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Perseus Proteomics's enterprise value is 円1,153.8 Mil.
Perseus Proteomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-744.6 Mil. Therefore, Perseus Proteomics's EV-to-EBITDA for today is -1.55.
The historical rank and industry rank for Perseus Proteomics's EV-to-EBITDA or its related term are showing as below:
TSE:4882'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.95 Med: -3.22 Max: -0.16
Current: -1.55
During the past 9 years, the highest EV-to-EBITDA of Perseus Proteomics was -0.16. The lowest was -11.95. And the median was -3.22.
TSE:4882's EV-to-EBITDA is ranked worse than 100% of 730
companies
in the Drug Manufacturers industry
Industry Median: 13.47
vs TSE:4882: -1.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Perseus Proteomics's PE Ratio (TTM) for today is calculated as:
Perseus Proteomics's share price for today is 円149.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Perseus Proteomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-48.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Perseus Proteomics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's EV-to-EBITDA falls into.
Perseus Proteomics's current Enterprise Value is 円1,153.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Perseus Proteomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-744.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a EV-to-EBITDA of -1.55 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Perseus Proteomics. According to the industry distribution chart, Perseus Proteomics ranks #999999 out of 730 companies in the Drug Manufacturers industry.
Is Perseus Proteomics' EV-to-EBITDA too high?
Perseus Proteomics' current EV-to-EBITDA is -1.55. Based on the distribution chart, Perseus Proteomics ranks #999999 out of 730 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perseus Proteomics has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #999999 out of 730 companies for EV-to-EBITDA. This places Perseus Proteomics in the lower half of its industry. The industry median EV-to-EBITDA is 13.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.47, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Perseus Proteomics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current EV-to-EBITDA is -1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円442.02, compared to a current price of 円149.00 — trading 66.3% below its estimated fair value. The current EV-to-EBITDA is -1.55. Perseus Proteomics' overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current EV-to-EBITDA is -1.55 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円149.00 is trading 66.3% below its estimated GF Value™ of 円442.02.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
EV-to-EBITDA: -1.55
GF Value™: 円442.02 vs. price of 円149.00 (66.3% below fair value)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
55GF Score
Get the complete analysis for TSE:4882
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
